Philadelphia, PANCT06984562Now EnrollingIRB Ready

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) Clinical Trial in Philadelphia, PA

Access cutting-edge locally advanced pancreatic ductal adenocarcinoma (pda) treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Fox Chase Cancer Center

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access locally advanced pancreatic ductal adenocarcinoma (pda) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related locally advanced pancreatic ductal adenocarcinoma (pda) treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this locally advanced pancreatic ductal adenocarcinoma (pda) clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) Study in Philadelphia

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment? Participants will: * Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.

Sponsor: Fox Chase Cancer Center

Who Can Participate

Inclusion Criteria

Patients must have histologically or cytologically-confirmed PDA.
Patients must have locally advanced unresectable PDA. • This includes the following- per NCCN criteria\*: 2.1 Unreconstructible involvement with the superior mesenteric vein or portal vein due to tumor or bland thrombus OR 2.2 Solid tumor contact with greater than 180 degrees of the superior mesenteric artery or celiac artery OR 2.3. Solid tumor contact with the aorta OR 2.4. Patients with non-metastatic disease that is inoperable by virtue of the operation posing excessive risk to the patient \*All patients must have been reviewed in the multidisciplinary conference and determined to have unresectable disease by a pancreatic surgeon and to have received or be ineligible for induction chemotherapy based on medical oncology assessment. Documentation of this review in EPIC meeting minutes will satisfy this requirement.
Patients enrolled onto the dose escalation arm may have started chemotherapy prior to initiation of radiation therapy and the last dose of chemotherapy must occur at least 2 weeks before start of ART.
Eastern Cooperative Oncology Group, or ECOG, performance status 0-2.
Adequate bone marrow, hepatic, renal function:
ANC ≥ 1,500/µl and PLT ≥ 100,000/µl
Bilirubin less than 1.5 ULN
AST and ALT \< 3X ULN
Serum Creatinine \<1.5X ULN
Women of childbearing potential must not be pregnant (negative pregnancy test within 72 hours prior to registration). Postmenopausal woman must have been amenorrheal and non-lactating for at least 12 months to be considered of non-childbearing potential. Men and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for at least 6 months after therapy is completed.
Age ≥ 18 years
Participants must sign a written informed consent and HIPAA consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment, tissue sample collections, and follow-up.

Exclusion Criteria

Radiologically or cytologically confirmed metastatic disease.
Patients who have had any prior radiation therapy for pancreatic cancer.
Patients who have had prior chemoradiation to an overlapping volume.
Patients with adenosquamous carcinoma of the pancreas.
Subjects who have had chemotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier to \< Grade 2. Patients who received previous immunotherapy or other antibody therapy, within 28 days (immune related toxicities must have resolved to \<= Grade 2 prior to starting treatment). Study treatment may be started within these washout periods or with continuing toxicities if considered by the Sponsor-Investigator to be safe and within the best interest of the patient.
Concurrent non-study chemotherapy or biologic therapy.
A history of ataxia telangiectasia or other documented history of radiation hypersensitivity. • Includes both bi- and mono-allelic likely pathogenic or pathogenic ATM mutations (VUS is acceptable).
Serious, active infections requiring treatment with IV antibiotics

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT06984562) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA) Treatment Options in Philadelphia, PA

If you're searching for locally advanced pancreatic ductal adenocarcinoma (pda) treatment options in Philadelphia, PA, this clinical trial (NCT06984562) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced locally advanced pancreatic ductal adenocarcinoma (pda) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all locally advanced pancreatic ductal adenocarcinoma (pda) clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Philadelphia, PA

See all leukemia clinical trials recruiting in Philadelphia — not just this study.

Browse Leukemia Trials in Philadelphia →

Browse More Trials by Condition

Leukemia TrialsAlzheimers Disease TrialsParkinsons Disease TrialsUlcerative Colitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA